Hims Hers Health Inc is trading 6.9% up at $27.94 as the stock extends a strong multi-week rally supported by increasingly bullish Wall Street views and growth optimism.
- JPMorgan reportedly initiated coverage on the company with an Overweight rating and a $35 price target, highlighting robust long-term growth prospects.
- Broader consensus Buy ratings and price targets in the $32–$35 range reinforce positive sentiment surrounding the company’s GLP-1 and telehealth opportunities.